A10 THE BULLETIN • MONDAY, MARCH 29, 2021
STATE OF
THE JABS
Wash.
N.H.
Mont.
Ore.
Vt.
N.D.
Minn.
Idaho
N.Y.
Wis.
S.D.
Wyo.
Mich.
Neb.
Nev.
Pa.
Iowa
Utah
Ill.
Ind.
Ohio
W.
Va.
Colo.
Calif.
Kan.
Ariz.
Okla.
N.M.
Mo.
Ky.
Texas
N.C.
Tenn.
Ark.
S.C.
Miss.
Alaska
Va.
Ala.
Ga.
La.
Fla.
Hawaii
Maine
By Charles Apple
| THE SPOKESMAN-REVIEW
Have you had your jab yet? Your Fauci
ouchie? Your first or second dose of corona-
virus vaccine? If not, don’t worry too much:
Officials have bought more doses and are
getting better at spreading them around the
country. President Joe Biden has set a goal of
making every adult in the
country eligible for a jab by
People in each state
who have received
the first of May and having
at least one dose
enough for every American
by the end of May. Here’s a
look at the three vaccines
Less
25%
More
being used now and a couple
than
to
than
25%
30%
30%
more that may be on the way.
Mass.
R.I.
Conn.
N.J.
Del.
Md.
D.C.
As of March 26
The three types of vaccines
now being used in the U.S. ...
Pfizer-
BioNTech
Official name
Emergency use
authorization issued
Type of vaccine
How
administered
Recommended
for
Reported
side effects
Effectiveness
in clinical trials
Storage
requirements
... and the two that
are still under consideration
Moderna
Johnson
& Johnson
Astra-
Zeneca
Novavax
BNT162b2
mRNA-1273
JNJ-78436735
AZD1222
NVX-CoV2373
Dec. 11, 2020
Dec. 18, 2020
Feb. 27, 2021
Still undergoing
clinical trials.
Still undergoing
clinical trials.
mRNA, meaning it’s
made with a piece of
the coronavirus called
a “spike protein.” It
does not use the entire
virus, so a patient
cannot catch COVID-19
from the vaccine. And
the mRNA never enters
the nucleus of the cells
of the human body.
mRNA
Viral vector,
meaning the vaccine
was created using a
modified version of
a virus similar to
COVID-19. The
vaccine cannot
cause COVID-19 and
it does not enter or
change a patient’s
DNA.
Viral vector, similar
to the Johnson &
Johnson vaccine.
The AstraZeneca
vaccine used spike
protein from an
adenovirus — a
type of common
cold common
among
chimpanzees.
“Recombinant nanopar-
ticle vaccine:” Genetic
material from COVID-19
spike protein cells are
injected into insect
viruses. Those infect
insect cells, which, in
turn, create more spike
protein. The end
product is enhanced
and packaged.
Two shots,
21 days apart, in
the muscle of the
upper arm.
Two shots,
28 days apart, in
the muscle of the
upper arm.
One shot in the
muscle of the
upper arm.
Two shots, four
to 12 weeks apart,
in the muscle of
the upper arm.
Two shots, three
weeks apart, in the
muscle of the
upper arm.
People age 16
and older.
People age 18
and older.
People age 18
and older.
People age 18
and older.
People age 18
and older.
Pain, redness and
swelling where
you get the shot.
Throughout the
rest of your body:
Tiredness,
headache, muscle
pain, chills, fever
and nausea.
Despite reports from
Europe and elsewhere of
patients developing
blood clots after
receiving this vaccine,
tests in the U.S. have not
duplicated this. The
manufacturer also says
the vaccine has been
effective in elderly
patients and against new
variants of COVID-19.
Novavax hasn’t yet
released informa-
tion on the side
effects of its
vaccine, but they’re
reportedly similar.
This vaccine is
reportedly 86.3%
effective against
some of the newer
variants of
COVID-19.
Pain, redness and swelling where you get
the shot. Throughout the rest of your
body: Tiredness, headache, muscle pain,
chills, fever and nausea. Most side effects
are mild to moderate and are more
common after the second dose.
Was 95% effective
at preventing
COVID-19 illness in
people without
evidence of
previous infection.
Was 94.1% effective
at preventing
COVID-19 illness in
people without
evidence of previous
infection.
Was 66.3% effective
at preventing
COVID-19 illness in
people without
evidence of
previous infection.
Was 79% effective
AstraZeneca said
Monday. A safety panel
said Tuesday the
company presented
misleading data.
Was 89.7% effective
at preventing
COVID-19 illness in
people without
evidence of previous
infection.
Shipped and stored
at ultralow tempera-
tures between -112°F
to -76°F. Once
thawed, vaccine can
be stored in a
refrigerator for up to
five days. Once at
room temperature,
vaccine must be used
within two hours.
Stored at freezer
temperatures between
-13°F to 5°F. Can then
be moved to a
refrigerator for up to
30 days. Once a vial of
vaccine has been used
once, it’s good for up
to six hours, as long as
the temperature does
not exceed 77°F.
Stored in a
refrigerator
between 36°F to
46°F. Once a vial
of vaccine has
been used once,
it’s good for up to
six hours in a
refrigerator or up
to two hours at
room temperature.
Stored up to six
months in a
refrigerator between
36°F to 46°F. Once a
vial of vaccine has
been used once, it’s
good for up to six
hours in a refrigera-
tor or up to two
hours at room
temperature.
Can be stored
up to six
months in a
refrigerator
between 36°F
to 46°F. Once a
vial reaches
room tempera-
ture, it’s good
for at least 24
hours.
Sources: Centers for Disease Control and Prevention, U.S. Food and Drug Administration, ClinicalTrials.gov, Immunize.org,
Prevention.com, ModernaTx.com, Genetic Engineering and Biotechnology News, European Medicines Agency
ALL PHOTOS FROM
THE ASSOCIATED PRESS